Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
December 09, 2024 12:00 ET
|
Aptose Biosciences, Inc.
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
December 03, 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
November 25, 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Aptose Reports Results for the Third Quarter 2024
November 08, 2024 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Special Meeting of Shareholders
September 05, 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Special Meeting of Shareholders
Aptose Announces Adjournment of its Special Meeting of Shareholders
August 15, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Reports Results for the First Quarter 2024
May 14, 2024 16:01 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the First Quarter 2024
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
May 06, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose to Report First Quarter 2024 Financial Results and
Provide Clinical Strategy Update on Tuesday, May 14, 2024
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
March 18, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and
Provide Corporate Update on Tuesday, March 26, 2024
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
January 26, 2024 08:00 ET
|
Aptose Biosciences, Inc.
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical